Diving Into Therapeutic Decision-Making in Later-Line CLL

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Nicole Lamanna, MD, shares key considerations for the use of pirtobrutinib in the management of chronic lymphocytic leukemia.

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.